Search PubMed⌕ Search

Biomedical subjects

A Germain

Publications and source records attributed to A Germain.

At least 19 recordsLinked to original sources
PubMed1992

[Pseudomyxoma of the peritoneum. Apropos of 4 cases].

Peritoneal pseudomyxoma is a rare disease (400 published cases). In 60% of all cases, an ovarian tumor is the cause of the disease. The second cause is appendicular mucocele. We report about four personal cases after a longer time lapse. No clinical or biological sign is specific. Ultrasonography associated to CT may allow establishing the preoperative diagnosis. Peritoneal pseudomyxoma has several main features: it is insidious, recurrent, obstinate and severe. Recent work has shown that peritoneal pseudomyxoma is secondary to malignant mucosecretory tumors, mainly of ovarian (cystadenocarcinoma) or appendicular origin, with intraperitoneal cell implants. Surgery is the only treatment with proven effectiveness. The effectiveness of chemotherapy and radiation therapy has not been established.

Aged↗
PubMed1991

Effect of maternal administration of thyrotropin releasing hormone on the preterm fetal pituitary-thyroid axis.

We evaluated the response of preterm fetuses to maternal intravenous injection of 400 micrograms of thyrotropin releasing hormone (TRH) between 30 minutes and 5 hours before delivery (n = 12). An additional seven mothers received saline solution and served as control subjects. There were no statistically significant differences in gestational age, birth weight, or Apgar scores between groups. At delivery, concentrations of maternal thyrotropin were elevated in the TRH group compared with the control group (12.0 +/- 1.6 vs 5.6 +/- 0.5 mU/L; p less than 0.005); however, maternal triiodothyronine (T3) values remained unchanged. Significant elevations of fetal thyrotropin and T3 were observed after maternal administration of TRH compared with control subjects (45.8 +/- 7.7 vs 8.4 +/- 0.9 mU/L (p less than 0.002) and 1.3 +/- 0.07 vs 0.7 +/- 0.04 nmol/L or 87 +/- 5 vs 49 +/- 3 ng/dl (p less than 0.001), respectively). Fetal thyroxine (T4) and prolactin values were also elevated after exposure to TRH (135 +/- 5 vs 86 +/- 10 nmol/L or 10.5 +/- 0.4 vs 6.7 +/- 0.8 micrograms/dl (p less than 0.001) and 212 +/- 31 vs 105 +/- 28 micrograms/L (p less than 0.05), respectively). Two hours after birth, a significant increase in T3 but not T4 levels was observed in both groups of infants. These data indicate that fetal exposure to a single dose of TRH via maternal administration of this hormone results in marked stimulation of the preterm fetal pituitary-thyroid axis, as in the fetus at term, and that this treatment does not inhibit the early postnatal surge of T3.

Female↗
PubMed1990

[The simultaneous measurement of cortisol and cortisone in the plasma and tissues by high-resolution liquid chromatography].

Measurement of cortisol (F) and cortisone (E) are important to study cortisol metabolism during gestation or in hypertensive patients. We developed a method for simultaneous measurement of F and E based on plasma extraction by dichloromethane, separation by high resolution chromatography and detection at 254 nm. Good correlation between this method and RIA was obtained in measurements of maternal plasma cortisol (r = 0.77). Retention times for F and E were 25 +/- 0.6 and 20 +/- 0.4 min respectively. F and E recovery was 73% (interassay coefficient 7.1%). Conversion of F to E in controls and in human placenta, but not in pseudohyperaldosteronism, is detected by the method. F values in maternal blood (269 +/- 12 ng/ml), umbilical artery (61 +/- 5), umbilical vein (44 +/- 3) and E values in maternal blood (40 +/- 1), umbilical artery (57 +/- 4) and umbilical vein (61 +/- 4), were similar to those reported in the literature. Thus, HPLC is a simple, reliable and reproducible method for measurement of cortisol and cortisone.

Chromatography, High Pressure Liquid↗